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ABSTRACT
PURPOSE: The greatest challenge in treating Clostridium difficile infection (CDI) is disease
recurrence, which occurs in about 20% of patients usually within 30 days of treatment cessation.
We sought to identify independent predictors of first recurrence among a national cohort of
Veterans with CDI.
METHODS: We conducted a case-control study among acute and long-term care Veterans
Affairs (VA) inpatients and outpatients with a first CDI episode (positive stool sample for C. difficile
toxin(s) and receipt of at least two days of CDI treatment) between 2010 and 2014. Cases
experienced first recurrence within 30 days from the end of treatment. Controls were those without
first recurrence matched 4:1 to cases on year, facility, and severity. Multivariable conditional
logistic regression was used to identify predictors of first recurrence.
RESULTS: We identified 32 predictors of first recurrence among 974 cases and 3,896 matched
controls. Significant predictors included medication use prior to (probiotics, fluoroquinolones,
laxatives, 3rd/4th generation cephalosporins), during (1st/2nd generation cephalosporins,
penicillin/amoxicillin/ampicillin, 3rd/4th generation cephalosporins), and after CDI treatment
(probiotics, any antibiotic, proton pump inhibitors [PPIs], and immunosuppressants).

Other

predictors included current biliary tract disease, malaise/fatigue, cellulitis/abscess, solid organ
cancer, and history of HIV, multiple myeloma, abdominal pain, and ulcerative colitis.
CONCLUSION: In our large national cohort of outpatient and acute and long-term care inpatients,
treatment with certain antibiotics, PPIs, immunosuppressants, and underlying disease were
among the most important risk factors for first CDI recurrence. Results highlight an important
opportunity for antibiotic stewardship programs to not only target inappropriate antibiotic use but
also unnecessary PPIs use, especially in patients with a history of CDI.

Keywords: Clostridium difficile infection, Veterans Affairs, recurrent disease, predictors
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INTRODUCTION
Clostridium difficile is a gram-positive anaerobe that causes infectious diarrhea that can range in
severity from mild to severe disease.1 One of the greatest challenges in treating Clostridium
difficile infection (CDI) effectively is the high recurrence rate. Reported CDI recurrence rates vary
substantially from about 5% to as high as 50% due to differing prevalence in risk factors and
definitions for recurrence between studies, however recurrence typically occurs in about 20% of
patients.2-5 Following the first recurrence, the risk of an additional episode of CDI increases to
between 45% and 65%.6 Recurrent CDI is challenging to treat and causes significant morbidity,
mortality and reductions in quality of life.7 Identifying those at highest risk for recurrence could
allow for targeted initial CDI management and may improve patient outcomes.2

Several risk factors for CDI recurrence have been identified in the general population.1,

8-11

Previously identified risk factors include, advanced age, use of certain medications, such as nonCDI active antibiotics, and gastric acid suppressants, as well as underlying comorbid or
immunocompromising conditions.1, 8-11 Previous studies have primarily focused on CDI diagnosed
and treated in acute care settings. CDI has become increasingly common in community and longterm care settings and patients often receive care from multiple clinical settings.12, 13 Current
estimates suggest that community-associated CDI accounts for over 20% of cases.14 Over 60%
of cases of healthcare-associated CDI cases may have had onset in long-term care facilities.13
This fragmented care for CDI among various settings poses a particular challenge for the accurate
identification of recurrent disease, as the facility that treats the index episode often may not be
the same facility that treats the recurrent episode.15

The Veterans Health Administration (VHA) is the United States’ largest integrated health care
system, with over 140 medical centers and 1,200 outpatient clinics and long-term care facilities.16
Utilization of VA data provides the unique opportunity to study predictors of recurrent CDI among
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patients diagnosed and treated across clinical settings. Moreover, the Veteran population is older,
has poorer health status, more medical conditions, and higher medical resource use than the
general population.17 The risk for recurrence in Veterans may be different than in the general
population highlighting the need for a comprehensive understanding of the predictors of first
recurrence among Veterans with an initial CDI episode.

Thus, our work sought to identify

independent predictors of first recurrence among a national cohort of Veterans with CDI.

METHODS
The study was approved by the Institutional Review Board and the Research and Development
Committee of the Providence Veterans Affairs Medical Center.

Patient Population and Study Design
We conducted a matched case-control study among adults (> 18 years) with a first CDI episode
treated in Veterans Affairs (VA) facilities nationally from May 1, 2010 to December 30, 2014. The
first episode of CDI was the first identified during the study period for each patient with no CDI
episodes in the year prior to study inclusion.18 A CDI episode was defined as a positive stool
sample for C. difficile toxin(s) regardless of testing method (however the majority of testing
throughout the VA is done through polymerase chain reaction) during an inpatient admission or
an outpatient encounter and receipt of at least two days of standard CDI treatment (oral or
intravenous [IV] metronidazole, oral or rectal vancomycin, or fidaxomicin).1, 19 The use of the
nucleic acid amplification test for CDI diagnostic testing among VA facilities increased from 33%
in 2010 to 81% in 2015.20 Similar to previous work, we used a window of at least two days of
therapy (at least one dose of drug on two days regardless of frequency) to represent exposure.21,
22

Two days was used to indicate real-world initiation of treatment, thus even if the episode

represented colonization, it was being treated as an infection.
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First recurrence was defined as a subsequent CDI episode (defined as a positive stool sample or
diagnosis code 008.45 for CDI and at least two days of subsequent CDI treatment) at least 14
days after the positive stool test date and within 30 days of the end of treatment of the initial CDI
occurrence. As above at least two days of therapy was required for exposure.21, 22 We used an
interval of at least 14 days to distinguish a new recurrent episode from the initial CDI episode
similar to previous work.2, 23 We assessed recurrence up to 30 days after treatment cessation as
most recurrences occur within 1-3 weeks after the end of treatment.2, 24, 25 Previous work has
shown that the risk for recurrence is greatest 10 days after treatment cessation.2 The definition
of recurrence within 28 to 30 days of the end of CDI treatment is commonly used in clinical trials.2527

Recurrence within 30-days has been used in previous VA and non-VA studies.28, 29 Cases

were defined as patients that experienced 30-day first recurrence and controls were defined as
those that did not experience 30-day first recurrence.

Controls were matched to cases with a 4 to 1 ratio, based on date of CDI episode (year), facility,
and severity. CDI was defined as severe if the closest white blood cell count was >15 x 103/μL
or the closest serum creatinine was >1.5 g/dL within 7 days of the index treatment date, nonsevere if white blood cell count was <15 x 103/μL and serum creatinine <1.5 g/dL, or otherwise
unknown.30 Of patients with a white blood cell count (n=42,298) and serum creatinine (n=40,261)
within 7 days, 96.3% and 96.0% were within 2 days of treatment, respectively.

Potential Predictors
We assessed 215 potential independent predictors of recurrence based on clinical relevance
and/or previous work.1, 8-11 All potential predictors assessed were selected a priori. Potential
predictors included socio-demographics (age, gender, race, ethnicity, and marital status), CDI
treatment, admitting source, current comorbidities and medical history (diagnosis codes) in the
previous 365 days, current and previous infections, laboratory results, current and previous
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surgeries and procedures, previous healthcare exposures, as well as medication exposures. All
comorbidities, medical history, and infections were assessed from diagnosis codes using the
Clinical Classifications Software (CCS) of the Agency for Healthcare Research and Quality
(AHRQ).31 CDI treatment was defined as metronidazole oral or IV monotherapy, vancomycin oral
or rectal monotherapy, vancomycin and metronidazole combination therapy, or fidaxomicin alone
or in combination with vancomycin and/or metronidazole.

Due to the frequency of use of

metronidazole monotherapy, we compared metronidazole monotherapy to all other treatment
options combined as a binary variable. NAP1/027 strain was assessed based on the reported
test name and results of the clinical specimen from the testing laboratory, where strain data was
available. Strain was defined as hypervirulent or unknown/non-hypervirulent otherwise.

Medication exposures assessed included antibiotic agents/classes, gastric acid suppressants,
immunosuppressant, laxatives, and supplemental medications.

Antibiotic agents/classes

exposure was assessed in the previous 30 days before CDI treatment, during CDI treatment, and
30 days after CDI treatment.
aminoglycosides;

Antibiotic exposures assessed were categorized as follows:

amoxicillin

or

ampicillin

/

Beta-lactamase

inhibitors;

penicillin/amoxicillin/ampicillins; aztreonam; carbapenems; anti-staphylococcal pencillins, antipseudomonal pencillins/ Beta-lactamase inhibitors, 1st/2nd generation cephalosporins; 3rd/4th
generation

cephalosporins;

clindamycin;

fluoroquinolones,

fosfomycin,

glyco-/glycolipo-

/lipopeptdes (except vancomycin oral/rectal), macrolides, nitrofurantoin, oxazolidinones,
polymyxins,
tigecycline.

sulfamethoxazole/trimethoprim,

quinupristin-dalfopristin,

tetracyclines,

and

Any antibiotic use was defined as the presence of exposure to any of these

agents/classes. Gastric acid suppressant use was assessed as histamine receptor 2 antagonists
or proton pump inhibitor use in the previous 7 days before CDI treatment, during CDI treatment,
and 30 days after CDI treatment.

Immunosuppressant medication use was defined as

corticosteroid, monoclonal antibody, antineoplastic, or transplantation agent use in the previous
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30 days before CDI treatment, during CDI treatment, and 30 days after CDI treatment. Laxative
use was assessed in the 2 days before CDI treatment. Supplemental medications included
probiotics, binding agents (i.e. colestipol, cholestyramine), and rifampin or rifaximin in the 30 days
before CDI treatment, during CDI treatment, and 30 days after CDI treatment.

Windows for

exposure to medications were selected based on clinical relevance or previous work.3,

11, 32

Figure 1 presents a timeline of when predictors were assessed.

Statistical Analysis
All analyses were performed using SAS (SAS Institute Inc., Cary, NC, Version 9.2). Demographic
and clinical characteristics of cases and controls were analyzed using chi-square or Fisher’s exact
tests for categorical data and Student’s t test or the Wilcoxon rank sum test for continuous data,
as appropriate. Independent predictors of first recurrence were identified utilizing backward
manual stepwise conditional logistic regression models.33 In univariate analyses, variables were
included in the subsequent multivariable model at a p-value of less than 0.10.33 Variables were
then removed from the multivariable model in a stepwise fashion until all remaining variables
within the final model demonstrated statistical significance (p-value <0.05).33 Absence of
collinearity between the variables in the final model was confirmed from tolerance and variance
inflation.33 Tolerance was above 0.1 and variance inflation was below 10 for all variables included
in the model (highest variance inflation was 2.07).

Subgroup analyses were conducted to determine whether predictors varied by initial CDI severity
(severe and non-severe) and treatment setting (acute care and outpatient).

RESULTS
We identified 49,064 patients with an initial CDI episode. The mean age of this cohort was 66.2
years (±14.1 SD), 93.5% were male (n=45,887), and 74.4% were white (n=36,524). Most patients
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with initial CDI were treated in the outpatient setting (69.6%, n=34,146), followed by acute care
(27.3%, n=13,396), and long-term care (2.1%, n=1,019). Of those with a first CDI treated in the
outpatient setting, 56.5% had a VA hospital admission within prior 90 days and 60.3% had an
antibiotic exposure within 30 days prior to CDI treatment. Initial treatment with metronidazole
monotherapy (83.3%, n=40,868 [71.5% oral and 28.6% IV]) was most common, followed by
vancomycin

oral/rectal

and

metronidazole

combination

(9.7%,

n=4,765),

vancomycin

monotherapy (6.9%, n=3,370). Severe CDI was observed in 34.3% (n=16,806) of patients and
mild CDI in 50.4% (n=24,713). First recurrence within 30 days of the end of treatment occurred
in 6.2% (n= 3,020) of patients with an initial CDI occurrence.

We identified 974 cases that experienced first recurrence and 3,896 controls matched on year,
facility and severity that did not experience first recurrence. Severe CDI was observed in 36.8%
of cases and controls, and mild CDI in 39.9% of cases and controls. As noted in Tables 1 and 2,
several significant differences between cases and controls were observed, including differences
in CDI treatment. Metronidazole monotherapy was used in 75.6% of cases (64% of which was
oral) and 90% of controls (66% of which was oral).

Our final multivariate model was used to calculate adjusted odds ratios [OR] and identified 32
independent predictors of first recurrence of CDI in Veterans, which are listed in Table 3. Strong
predictors included use of probiotics (odds ratio [OR] 4.62, 95% CI 2.37-8.98), fluoroquinolones
(OR 3.35, 95% CI 2.58-4.34), laxatives (OR 2.35, 95% CI 1.21-4.58), and 3rd/4th generation
cephalosporins (OR 2.04, 95% CI 1.49-2.79) prior to initial CDI treatment. Other predictors
included medication use during the initial CDI treatment (1st/2nd generation cephalosporins, OR
1.92, 95% CI 1.13-3.25; penicillin/amoxicillin/ampicillin, OR 1.70, 95% CI 1.06-2.71; and 3rd/4th
generation cephalosporins, OR 1.54, 95% CI 1.13-2.11) and in the 30 days after CDI treatment
(probiotics, OR 2.30, 95% CI 1.35-3.91; any antibiotic, OR 2.14, 95% CI 1.68-2.73; proton pump
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inhibitors [PPI], OR 2.02, 95% CI 1.59-2.55, and immunosuppressants, OR 1.45, 95% CI 1.052.00).

Several current comorbidities and history of medical conditions were also identified as predictors:
current biliary tract disease (OR 4.70, 95% CI 1.68-13.12), malaise/fatigue (OR 2.38, 95% CI
1.01-5.64), cellulitis/abscess (OR 1.797, 95% CI 1.03-3.15), solid organ cancer (OR 1.79, 95%
CI 1.25-2.55), medical history of HIV (OR 3.32, 95% CI 1.26-8.78), multiple myeloma (OR 2.75,
95% CI 1.04- 7.27), abdominal pain (OR 2.47, 95% 1.65-3.70) ulcerative colitis (OR 2.14, CI 95%
1.01-4.57). White race was a significant predictor of first recurrence (OR 6.0, 95% CI 4.7-7.6).

Results of subgroup analyses by CDI severity and treatment setting can be found in the
supplemental material. Use of probiotics and fluoroquinolones prior to initial CDI treatment, use
of any antibiotic and PPI after CDI treatment, a principal diagnosis of CDI, and white race
remained significant predictors of first recurrence in all subgroups assessed.

DISCUSSION
Our study identified important independent predictors of first recurrence among our national
cohort of Veterans with initial CDI. Our study includes patients with CDI diagnosed and treated
in various healthcare settings, including both acute and long-term care inpatients and outpatients,
and focuses on the Veteran population. While several studies have assessed predictors of
recurrence in patients with CDI, data on recurrence predictors among the Veteran population are
limited.3, 11, 28, 32, 34

Antibiotic use is a well-established risk factor for recurrent CDI.3, 11, 32 Our results confirm that
antibiotic use before, during, and after treatment of the initial CDI episode were strongly
associated with recurrence. It is thought that antibiotic use during and after CDI treatment alters
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the recovering colonic microbiota and contributes to an increased risk for CDI recurrence.35 Three
meta-analyses and/or systematic reviews have shown that continued antibiotic use during and/or
after CDI treatment are among the most common risk factors for recurrence.3, 11, 32 We also
confirmed that gastric acid suppression was associated with an increased risk of recurrence
among Veterans. Gastric acid suppression is thought to increase the risk of infection through
allowing increased passage of C. difficile spores beyond the stomach leading to infection.11, 36
Previous studies have demonstrated an increased risk of CDI recurrence associated with PPI use
and to a lesser extent histamine 2 receptor antagonists (H2RA) use.3, 11, 37, 38 We found that
patients treated with PPIs after CDI treatment had an increased risk of CDI recurrence. Similar
results were observed among another national cohort of 22,615 Veterans, which found prior
antibiotic use and PPI use were predictors of 60-day CDI recurrence.34

Our results confirmed that several antibiotic classes used prior to (specifically, fluoroquinolones,
3rd-4th generation cephalosporins, penicillin/ amoxicillin/ or ampicillin, amoxicillin or ampicillin /
beta-lactamase inhibitors, 1st -2nd generation cephalosporins, and glyco-/ glycolipo-/ lipopeptide)
and during CDI treatment (specifically, 1st -2nd generation cephalosporins, penicillin/ amoxicillin/
or ampicillin, 3rd-4th generation cephalosporins, and glyco-/ glycolipo-/ lipopeptides) were
associated with an increased risk of recurrence as was use of any antibiotic not used for the
treatment of CDI (thus all antibiotics but metronidazole, vancomycin oral/rectal, or fidaxomicin)
after CDI treatment. In the previously mentioned VA study, the only antibiotic class independently
associated with 60-day recurrence was prior 3rd-4th generation cephalosporin use.34 While we
also identified prior 3rd-4th generation cephalosporin use as an independent predictor, the other
classes we identified may be related to the differences in exposure periods assessed between
the two studies (90 days prior versus 30-days prior, during, and after CDI treatment in our study).

11
Several studies have been conducted to evaluate the comparative risk of CDI associated with
different antibiotic classes.39-41

These studies have demonstrated the greatest risk with

clindamycin, where odds ratios have been as high as 20 compared to no antibiotics. Agents most
commonly associated with a moderate CDI risk include fluoroquinolones, carbapenems,
cephalosporins, and penicillins. The frequency and duration of use must also be considered when
evaluating risk estimates for different antibiotic classes. Despite the highest risk of CDI being
associated with clindamycin in other studies, it was not an independent predictor of recurrence in
our study, which may have been due to low utilization in our high-risk older patient population (4%
of patients in the 30 days prior to CDI, 2% during CDI treatment, and 1% after CDI treatment).
Similarly, carbapenem use was not a significant predictor of CDI recurrence and was used only
used in 3%, 7%, and 4% of patients in the 30 days prior, during, and after CDI treatment,
respectively. Fluoroquinolones were associated with the greatest risk of CDI recurrence in our
study (OR 3.4, 95% CI 2.6-4.3); while the risk of CDI recurrence with other antibiotic classes were
all similar to each other (ORs range ~1.5-2). Fluoroquinolones are among the most commonly
used antibiotics, often inappropriately, and are associated with a moderate risk of CDI.39, 42 In our
study, approximately 11% of controls and 35% of cases were exposed to fluoroquinolones in the
30 days before the initial CDI episode. Our results call for additional efforts in discontinuing
inappropriate antibiotics, particularly the overuse of fluoroquinolones, in situations where
antibiotics are avoidable. It is also important to note that, not all antibiotics may confer an
increased risk of recurrent CDI.19

Among Veterans with spinal cord injury and disorder,

tetracycline use was protective against recurrence.19 In another non-VA study, patients that
received doxycycline had a lower risk of CDI.43

Further, future work should assess which

concomitant antibiotics are most appropriate for patients in situations where antibiotics are
necessary and unavoidable.
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Probiotics, such as Lactobacillus, Bifidobacteria, or Saccharomyces boulardii, are thought to
restore the colonic microbiota in the setting of recurrent CDI, however the role of these agents in
treatment or prevention of recurrent CDI is unclear.44 Initial studies suggested that probiotic use
may decrease CDI recurrence when used as adjunctive treatment with vancomycin, however later
trials did not confirm these findings.45-47 We found that probiotic use prior to and after CDI
treatment were actually associated with an increased risk for CDI recurrence (prior: OR 4.62, 95%
CI 2.37-8.98, after: OR 2.30, 95% CI 1.35-3.91). A possible explanation for this unexpected
finding is that patients at an increased risk for recurrence were recognized as such by physicians
and were prescribed probiotics. For example, exposure to antibiotics, particularly higher risk
agents such as fluoroquinolones, may have prompted physicians to prescribe probiotics
potentially driving our findings.

We also found that laxative exposure prior to CDI treatment was a strong predictor of CDI
recurrence, a relationship that has not been previously evaluated. However, receipt of a laxative
has previously been identified as a predictor of development of CDI.48 Since laxative use distorts
the symptoms of CDI and positive stool samples among those exposed to laxatives may represent
colonization versus true infection, we hypothesized laxative exposure prior to the initial CDI
episode would not be a significant predictor of subsequent disease recurrence. Our somewhat
discordant findings may be related to differences in CDI treatment and potential disease severity
between cases and controls exposed to laxatives. Metronidazole monotherapy was used in only
60% of cases exposed to laxatives (n=30) as compared to 90% of controls exposed to laxatives
(n=68). Standard practice and CDI treatment guideline recommendations at the time of our study
supported the use of vancomycin over metronidazole for severe CDI episodes since
metronidazole use has been associated with poorer outcomes and higher recurrence rates in
patients with severe CDI episodes.1, 49, 50 Thus, differences in CDI treatment patterns among
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cases and controls exposed to laxatives may suggest that cases were sicker than controls
possibly leading to increased recurrence among the cases exposed to laxatives.

Similar to previous findings we found that certain underlying current or previous (in the year prior)
comorbid conditions and immunodeficiency were associated with CDI recurrence.36, 51, 52 We
found that current biliary tract disease and history of abdominal pain, enteritis and colitis,
esophageal disorder, and nutrition deficiency were all predictors of recurrence. These conditions
may be associated with dysfunction of the intestinal microbiota and/or reduced gastric acid
secretion, which may contribute to C. difficile colonization, infection, and recurrence.53 Patients
with these conditions may take gastric acid suppressants or laxatives, but upon further
investigation these medication exposures did not appear to be driving findings. Impaired immune
response to C. difficile toxins has also been shown to contribute to an increased risk of CDI
recurrence.54 Immunosuppressant use after CDI treatment, current malaise and fatigue, and solid
organ cancer, history of HIV infection, multiple myeloma, diabetes mellitus, and COPD were all
risk factors for CDI. Immunologic impairment associated with these conditions may contribute to
the higher risk of recurrence found in these patients. It is expected that some of these conditions,
for example abdominal pain and malaise and fatigue, may correspond with CDI diagnosis as they
are symptoms of CDI, and therefore were commonly reported in the time periods assessed.

Other notable predictors of recurrence identified were having a primary diagnosis of CDI and
demographic factors. In a single center retrospective chart review, primary diagnosis of CDI was
one of the most prevalent risk factors for CDI recurrence.55 In the hospital setting, a primary
diagnosis often represents the main reason for hospitalization. Therefore, this finding may be
related to CDI severity, as patients with a primary diagnosis of CDI may have severe CDI
symptoms that result in an inpatient hospitalization as compared to those with less severe
symptoms.55 For demographic factors, we found that white race as compared to non-white race
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was strongly associated with an increased risk of first CDI recurrence (OR 6.0, 95% CI 4.7-7.6).
In previous studies, associations between race and ethnicity and risk of recurrence have been
inconsistent.44, 56, 57 Upon further analysis our results do not appear to be driven by differences in
CDI treatment and are unlikely due to regional differences as we matched at the facility level. Our
findings could be due to differences in genetics, healthcare utilization or treatment patterns, or
other factors.

Our study found that the rate of first recurrence within 30 days of the end of treatment was 6.2%.
Our recurrence rates are lower than a recently published national VA study, which found that of
7,538 Veterans with a first CDI episode, 1,223 (16.2%) experienced recurrence within 60 days
post-treatment.34 Differences in rates of recurrence are likely due to differing definitions used to
define CDI episodes (IC9-code and positive laboratory value versus positive laboratory value and
CDI treatment in our study), differing lengths of follow-up to identify recurrence (60 days versus
30 days post treatment in our study), and different study periods (2002 to 2014 versus 2010 to
2014 in our study).34 Our CDI recurrence rates would have been higher had we extended followup for recurrence. It has been reported that CDI recurrence occurs at a rate of 7% to 26% at 30
days.18 A previous national VA study of 30,326 Veterans with first CDI reported rates of 30-day,
60-day, and 90-day recurrence by CDI type.28 In this study, the majority of patients (60%,
n=18,260) had health care facility onset CDI and those with health care facility onset CDI had the
lowest rates of 30-day recurrence (7.2%). Recurrence rates only increased to 9.5% at 60 days
and 10.6% at 90 days.

There are a few limitations to this work. We defined incident CDI, as the first episode during the
study period, with no history of CDI in the year prior to that initial CDI episode. Therefore, the
incident CDI may not represent the first episode ever for all patients. Our definition of C. difficile
was based on laboratory results and did not include assessment of clinical symptoms (diarrhea),
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and the potential for misclassification of CDI symptomatic episodes versus asymptomatic carriage
exists. We did require receipt of at least two days of standard CDI treatment. This practice of
combining drug and laboratory data has been used previously, however capturing only clinically
relevant disease remains a challenge when using large datasets.30 Vancomycin, metronidazole,
and fidaxomicin given orally were the primary antibiotics given for treatment of CDI during our
study period. However, in patients with an ileus who cannot tolerate oral medications, they may
be given metronidazole IV or vancomycin rectal.1 In order to avoid excluding the most severely
ill patients, we allowed for metronidazole IV and vancomycin rectal monotherapy to meet our
definition of “standard CDI treatment”.1 There is the potential for misclassification of true disease
in asymptomatic patients with positive lab tests treated with metronidazole IV for another infection.
Another limitation was that we are unable to account for possible treatment or healthcare outside
the VA system. In particular, we are unable to account for any over-the-counter medication use
not filled in VA pharmacies, such as PPI, H2RAs, and probiotics, and for patients that may have
had their initial CDI or recurrence treated outside of the VA system.

Severity was selected a priori as a matching factor in the statistical analysis plan for this study as
it is a known predictor of poor outcomes. However, our definition of severity is limited as we only
had a single serum creatinine level near CDI treatment initiation, and thus could not assess
change from baseline as recommended in the 2010 Infectious Diseases Society of America CDI
guidelines which were the guidelines used during our study period (2010-2014).1 Additionally, lab
values were not available on all patients to assess severity. Only having one lab value at baseline,
may have led to misclassification of patients into the “severe” category. Treatment patterns of
cases and controls suggest this may be minimal as 37% of cases and controls were classified as
severe, and about 36% of cases and 33% of controls were treated with options recommended by
current guidelines for more severe disease (oral vancomycin, IV metronidazole, or combination
therapy).1 However, despite only 40% of cases and controls being categorized as “non-severe”,
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about 66% were treated with metronidazole oral monotherapy, suggesting an underestimation of
non-severe disease.1 We would not expect misclassification of severity to be differential by case
control status. Strain type was also unknown for most patients.

As previously mentioned, had we extended the follow-up period for CDI recurrence, rates would
have been higher. However, a priori we chose to study 30-day recurrence since previous work
has demonstrated that CDI recurrence usually occurs within 30 days following the end of CDI
treatment, with most cases occurring within 1-3 weeks after treatment.2, 24, 25, 54, 58 Additionally,
most clinical trials have assessed outcomes at 28 to 30 days from the end of treatment. A recent
systematic review of CDI treatments in 24 randomized controlled trials reporting recurrence rates,
found that follow-up time was between 21 and 30 days from end of treatment for all studies except
one which reported outcomes at 56 days only.59 While the length of follow-up used in clinical
trials has been consistently within 4 weeks of treatment cessation, that of studies assessing risk
factors for CDI recurrence has varied substantially.3, 59 A systematic review of 33 studies which
investigated risk factors for recurrent CDI found that recurrence definitions ranged from less than
21 days to over 180 days from the previous CDI episode.3 Additionally, accurate identification of
recurrent disease from administrative data is challenging.15

Previous work has shown

performance of diagnosis codes, laboratory data, or medication data used alone to accurately
identify recurrent disease is poor, and performance only improved moderately when used in
combination.15

Another limitation is that our results on the frequency of metronidazole use are reflective of the
practice patterns as recommended by the 2010 IDSA guidelines. Since publication of these
guidelines, several studies have demonstrated superiority of oral vancomycin over
metronidazole.60-62 As such current clinical practice and new 2017 guideline recommendations
recommend oral vancomycin over metronidazole first line despite disease severity.61, 63 The high
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frequency of metronidazole use in our study cohort limited our ability to evaluate other standard
CDI treatment options (vancomycin or fidaxomicin) individually. The generalizability of this work
to the general population is limited, as the Veteran population consists primarily of older White
males. There may be other unknown predictors that were not included in our study, or known
predictors that we could not capture from our data source.

Similar

to previous findings,

treatment

with non-CDI

active antibiotics,

PPIs,

and

immunosuppressants, as well as underlying comorbid and immunocompromising conditions were
among the most important risk factors for recurrence. Knowledge of predictors could help to
optimize management of initial CDI and lower risk of recurrence. Specifically, our results highlight
an important opportunity for multidisciplinary providers to not just target inappropriate antibiotic
use but also to reduce inappropriate use of PPIs, especially in patients with a history of CDI. As
with antibiotics, PPIs are a grossly overused class of medications with important consequences,
such as the increased risk for first recurrence.64 Multidisciplinary providers should be aware of
the changing clinical practice in CDI treatment and the increasing role vancomycin oral will play
in the treatment of initial disease despite severity.

CONCLUSION
In our large national cohort of outpatient and acute and long-term care inpatients, treatment with
antibiotics, PPIs, immunosuppressants and underlying disease were among the most important
risk factors for first CDI recurrence. Results highlight an important opportunity for antibiotic
stewardship programs to not only target inappropriate antibiotic use but also unnecessary PPI
use, especially in patients with a history of CDI.
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KEY POINTS:
•

A national case-control study among acute, long-term care, and outpatient Veterans with a
first CDI episode identified 32 predictors of first recurrence among 974 cases and 3,896
matched controls.

•

Treatment with antibiotics, proton-pump inhibitors (PPIs), immunosuppressants, and
underlying disease were among the most important risk factors for CDI recurrence identified.

•

Results highlight an important opportunity for antibiotic stewardship programs to not only
target inappropriate antibiotic use but also unnecessary PPIs and probiotic use, especially in
patients with a history of CDI.
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Table 1. Clinical characteristics, current comorbidities, medical history of patients with
first CDI occurrence by case-control status
Cases

of

first Controls

without

first P-

recurrence

recurrence

(n = 974)

(n = 3,896)

67.8 (±13.6)

64.8 (±13.9)

Male gender

920 (94.5)

3,604 (92.5)

0.034

White race

730 (75.2)

1,617 (41.5)

<0.001

Hispanic ethnicity

33 (3.4)

263 (6.8)

<0.001

Married

427 (43.8)

1,557 (40.0)

0.028

Severe

358 (36.8)

1,432 (36.8)

Non-severe

389 (39.9)

1,556 (39.9)

Unknown

227 (23.3)

908 (23.3)

55 (5.7)

259 (6.7)

Age (years), mean

value

<0.001

(SD)

CDI Severity

Hypervirulent strain
CDI treatmenta
Metronidazole

<0.001
736 (75.6)

3,506 (90.0)

monotherapy
Oral Route

625 (64.2)

2,586 (66.3)

IV Route

111 (11.4)

920 (23.6)

Vancomycin oral
96 (9.9)
monotherapy

0.255

35 (0.9)

25
Metronidazole
Oral/IV

& 142 (14.6)

343 (8.8)

vancomycin Oral
CDI

treatment

duration

<0.001

(days), 10.2 (±6.1)

8.4 (±6.2)

mean (SD)
Current
comorbidities
Biliary

tract

<0.001
25 (2.6)

39 (1.0)

23 (2.4)

21 (0.5)

49 (5.0)

74 (1.9)

disease
Malaise

and

<0.001

fatigue
Cellulitis

or

<0.001

abscess
Solid

organ

<0.001
132 (13.6)

206 (5.3)

64 (6.6)

203 (5.2)

0.095

142 (14.6)

273 (7.0)

<0.001

227 (23.3)

361 (9.3)

182 (18.7)

349 (9.0)

270 (27.7)

451 (11.6)

cancer
Pneumonia
Medical history
Heart failure
Chronic

<0.001

respiratory disease
Chronic

renal

<0.001

disease
Diabetes mellitus

<0.001
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Cerebrovascular

<0.001
51 (5.2)

76 (2.0)

92 (9.5)

232 (6.0)

Abdominal pain

85 (8.7)

125 (3.2)

<0.001

Osteoarthritis

126 (12.9)

161 (4.1)

<0.001

Atherosclerosis

238 (24.4)

349 (9.0)

<0.001

209 (21.5)

316 (8.1)

116 (11.9)

233 (6.0)

disease
Alcoholic

<0.001

disorder

Esophageal

<0.001

disorder
Nutrition

<0.001

deficiency
Data are number (%) unless otherwise stated.
CDI= Clostridium difficile infection; SD= standard deviation

a

Metronidazole monotherapy for Clostridium difficile infection was compared to all other

Clostridium difficile infection treatments combined. This variable was removed from the
multivariable model during the stepwise removal process and as such was not included in the
final multivariate model (Table 3).
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Table 2. Healthcare and medication exposures of patients with first CDI occurrence by
case-control status

Cases

Controls

P-

without

value

of

first
first
recurrence
recurrence
(n = 974)
(n = 3,896)
Treatment setting

<0.001

Acute care

397 (40.8)

970 (24.9)

Long term care

25 (2.6)

82 (2.1)

Outpatient

552 (56.7)

2,844
(73.0)
2,249
Veterans Affairs hospitalization, prior 90 days

<0.001

686 (70.4)
(57.7)

Veterans Affairs long-term care admission, prior 90 days

52 (5.3)

Non-CDI active antibiotic use, 30 days before CDI

71 (1.8)

<0.001

2,335

0.737

578 (59.3)
treatment

(59.9)
2,473

Non-CDI active antibiotic use, during CDI treatment

<0.001

503 (51.6)
(63.5)

Non-CDI active antibiotic use, 30 days after CDI

<0.001
487(50.0)

1267 (32.5)

58 (6.0)

346 (8.9)

309 (31.7)

1390 (35.7)

treatment
Histamine receptor 2 antagonist use, 7 days before CDI

.003

treatment
Proton pump inhibitor use, 7 days before CDI treatment

0.021
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Histamine receptor 2 antagonist use, 30 days after CDI

<0.001
121 (12.4)

325 (8.3)

treatment
1,310
Proton pump inhibitor use, 30 days after CDI treatment

<0.001

503 (51.6)
(33.6)

Probiotic use, 30 days before CDI treatment

80 (8.2)

31 (0.8)

<0.001

Probiotic use, 30 days after CDI treatment

89 (9.1)

85 (2.2)

<0.001

Immunosuppressant use, 30 days before CDI treatment

145 (14.9)

509 (13.1)

0.136

Immunosuppressant use, 30 days after CDI treatment

256 (16.0)

327 (8.4)

<0.001

Length of stay (days), median (IQR)

8 (4-18)

9 (5-20)

0.04

Data are number (%) unless otherwise stated.
CDI= Clostridium difficile infection; IQR= interquartile range
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Table 3. Independent predictors of first recurrence in patients with initial Clostridium
difficile infection
Predictor

Adjusted

Odds

Ratio (95% CI)
Medications used within 30 days before CDI treatment
Probiotic

4.62 (2.37-8.98)

Fluoroquinolone

3.35 (2.58-4.34)

Laxative (within 2 days before)

2.35 (1.21-4.58)

3rd-4th generation cephalosporin

2.04 (1.49-2.79)

Penicillin, amoxicillin or ampicillin

1.70 (1.07-2.70)

Amoxicillin or ampicillin / Beta-lactamase inhibitor

1.69 (1.08-2.66)

1st -2nd generation cephalosporin

1.68 (1.13-2.48)

Glyco-/ glycolipo-/ lipopeptide

1.54 (1.12-2.12)

Concurrent medications used during CDI treatment
1st -2nd generation cephalosporin

1.92 (1.13-3.25)

Penicillin, amoxicillin or ampicillin

1.70 (1.06-2.71)

3rd-4th generation cephalosporin

1.54 (1.13-2.11)

Medications used within 30 days after CDI treatment
Probiotic use

2.30 (1.35-3.91)

Any non-CDI active antibiotica

2.14 (1.68-2.73)

Proton pump inhibitor

2.02 (1.59-2.55)

Immunosuppressant

1.45 (1.05-2.00)

Current comorbidities
Biliary tract disease

4.70 (1.68-13.12)

Malaise and fatigue

2.38 (1.01-5.64)

30
Cellulitis or abscess

1.80 (1.03-3.15)

Solid organ cancer

1.79 (1.25-2.55)

Medical history
HIV infection

3.32 (1.26-8.78)

Multiple myeloma

2.75 (1.04-7.27)

Abdominal pain

2.47 (1.65-3.70)

Regional enteritis and ulcerative colitis

2.14 (1.01-4.57)

Osteoarthritis

1.89 (1.32-2.71)

Atherosclerosis

1.84 (1.38-2.46)

Esophageal disorder

1.66 (1.23-2.23)

Nutrition deficiency

1.63 (1.15-2.30)

Diabetes mellitus

1.59 (1.21-2.09)

Chronic obstructive pulmonary disease

1.35 (1.01-1.82)

Clinical characteristics
Principal diagnosis of CDI

4.06 (2.97-5.55)

Treatment duration of initial CDI episode

1.04 (1.02-1.06)

Demographics
White raceb

5.95 (4.66-7.61)

The adjusted odds ratios are estimated from multivariate analysis of the data. The final
multivariate model included all predictive variables listed in the table above (odds ratio >1) and
also the following variables with odds ratios <1: histamine receptor 2 antagonist use within 7 days
before Clostridium difficile infection treatment, proton pump inhibitor use within 7 days before
Clostridium difficile infection treatment, any non-CDI active antibiotic during Clostridium difficile
infection treatment, current thyroid disorder, current pneumonia, medical history of a bacterial
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infection (unspecified site), medical history of biliary tract disease, abnormal albumin level,
nursing home admitting source, and Hispanic ethnicity .

a

Any antibiotic included any antibiotic not used for the treatment of CDI, including the following

aminoglycosides, aztreonam, β-lactam/ β-lactamase inhibitor combinations, carbapenems,
cephalosporins, clindamycin, fluoroquinolones, fosfomycin, glyco-/glycolipo-/lipopeptdes (except
vancomycin oral/rectal), nitrofurantoin, macrolides, oxazolidinones, penicillins, polymyxins,
sulfamethoxazole/trimethoprim, quinupristin-dalfopristin, tetracyclines, and tigecycline.

b

White race was compared to all other non-white races.

CDI= Clostridium difficile infection
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Figure 1. Timeline of when potential predictors for first CDI recurrence were assessed.
CDI= Clostridium difficile infection

Concurrent medications use
during initial CDI Episode

Current comorbidities
Medical history (comorbidities
within 1 year prior to initial CDI
episode)

Medication use (within 30 days
prior to treatment of initial CDI
episode)

30-days prior to FIRST day of
treatment of initial CDI episode

Laboratory measurements

Clinical characteristics

Demographics

First day of treatment
of initial CDI episode

Medication use
(within 30 days after
treatment of initial
CDI episode)

30-days after LAST day of
treatment of initial CDI episode
Last day of
treatment of initial
CDI episode
Cases = 30-day CDI first
recurrence
Controls = No 30-day CDI
first recurrence

